Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
MYND Life Sciences ( (TSE:MYND) ) has provided an announcement.
MYND Life Sciences has successfully concluded its debenture settlement agreement, eliminating $3.5 million CDN of debt from its balance sheet, which will be reflected in its upcoming financial statements. This financial milestone coincides with a leadership transition where Colin Campbell steps down as CEO, continuing as a Director while the company seeks a new CEO to advance its clinical testing and commercialization of its depression biomarker test.
More about MYND Life Sciences
MYND Life Sciences Inc. is a clinical-stage life sciences company focused on developing and commercializing a proprietary biomarker test aimed at diagnosing and monitoring Major Depressive Disorder (MDD) and Treatment-resistant Depression (TRD). The company aims to address the unmet need in depression diagnosis through personalized patient management strategies, leveraging its unique intellectual property.
YTD Price Performance: -6.67%
Average Trading Volume: 4,605
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $2.33M
Find detailed analytics on MYND stock on TipRanks’ Stock Analysis page.
